These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 16778139)

  • 1. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
    Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
    Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
    Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.
    Zhao L; Xie F; Tong X; Li H; Chen Y; Qian W; Duan S; Zheng J; Zhao Z; Li B; Zhang D; Zhao J; Dai J; Wang H; Hou S; Guo Y
    MAbs; 2014; 6(3):740-8. PubMed ID: 24670986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma.
    Stein R; Balkman C; Chen S; Rassnick K; McEntee M; Page R; Goldenberg DM
    Leuk Lymphoma; 2011 Feb; 52(2):273-84. PubMed ID: 21133722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.
    Zeng J; Liu R; Wang J; Fang Y
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):1899-907. PubMed ID: 25773122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
    Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
    Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions.
    Nishida M; Teshigawara K; Niwa O; Usuda S; Nakamura T; Ralph P; Newman R; Padlan EA
    Int J Oncol; 2008 Jun; 32(6):1263-74. PubMed ID: 18497988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
    Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
    MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
    Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
    Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
    Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
    Carnahan J; Stein R; Qu Z; Hess K; Cesano A; Hansen HJ; Goldenberg DM
    Mol Immunol; 2007 Feb; 44(6):1331-41. PubMed ID: 16814387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
    Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
    Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
    DeNardo GL; Tobin E; Chan K; Bradt BM; DeNardo SJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7075s-7079s. PubMed ID: 16203805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.
    Stein R; Gupta P; Chen X; Cardillo TM; Furman RR; Chen S; Chang CH; Goldenberg DM
    Blood; 2010 Jun; 115(25):5180-90. PubMed ID: 20101022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
    Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
    Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.